2026-11-20 · Artemisine Editorial Team
The World Health Organization (WHO) released new data on 16 November 2026 showing that, while more countries have developed national plans to tackle antimicrobial resistance (AMR), major gaps in testing and treatment still leave many patients at risk. The findings were published ahead of World AMR Awareness Week, held 18 to 24 November under the 2026 theme "One Health, one action: Prevent AMR now".
When medicines lose effectiveness against resistant bacteria and other microbes, common infections become harder to treat and routine procedures, including surgery, childbirth and cancer care, become riskier. In 2023, approximately 1 in 6 laboratory-confirmed bacterial infections worldwide were resistant to antibiotics. Against that backdrop, 173 countries now report having AMR plans, more than double the 79 that reported doing so in 2017.
Having a plan, however, does not mean patients are protected. Only 22 percent of countries report having both the necessary funding and full implementation of their national AMR action plans. WHO describes gaps along the whole pathway of care, from preventing infections to diagnosing and treating patients and detecting resistance trends. The findings come from the latest Tracking Antimicrobial Resistance Country Self-assessment Survey (TrACSS), completed by 183 countries, or 94 percent of Member States, in 2026. Established in 2016 by the Quadripartite organizations FAO, UNEP, WHO and WOAH, TrACSS is the only global mechanism monitoring how countries implement national AMR actions.
Diagnostic capacity is the weakest link. Only 36 percent of countries report a national reference laboratory equipped to test the selected bacteria and fungi, far short of the global target of 80 percent having comprehensive resistance testing capacity by 2030. Only 63 percent report guidelines on appropriate antimicrobial use, and just over half report surveillance systems monitoring national antibiotic use and AMR levels. WHO warns that inadequate diagnostic access increases the risk of ineffective or unnecessary antibiotic prescriptions, lets resistant outbreaks go undetected, and limits understanding of local resistance patterns. To help close the gaps, WHO released two practical tools under the AMR Diagnostic Initiative: a prioritized catalogue of diagnostic tests and step-by-step methods for clinical laboratories.
WHO Director-General Dr Tedros Adhanom Ghebreyesus said national plans are essential but "an unfulfilled plan helps no one", calling on countries to invest in infection prevention, surveillance, equitable access to essential antimicrobials and quality diagnostics. For procurement teams, distributors and health programmes, the data underline two parallel needs: dependable supply of quality-assured essential antibiotics and the diagnostic capacity to use them correctly. As countries move from plans to funded implementation, tenders are likely to weigh documented quality, batch traceability, registration dossiers and reliable availability of both antibiotics and diagnostic tests alongside price. Suppliers pairing essential antimicrobials with the documentation and stewardship support national programmes require will be better positioned.
Source: WHO, More countries have antimicrobial resistance plans but patients still lack testing and treatment, https://www.who.int/news/item/16-11-2026-more-countries-have-antimicrobial-resistance-plans-but-patients-still-lack-testing-and-treatment